One month use of Systane^® improves ocular surface parameters in subjects with moderate symptoms of ocular dryness

Figures & data

Figure 1 Chemical composition and mechanism of action of Systane^® Lubricating Eye Drops.

Table 1 Inclusion and exclusion criteria

Condition	Criteria
Inclusion criteria	Subjects who answer “some of the time”, “half of the time”, “most of the time”, or “all of the time” to the question “how often have your eyes felt dry enough to want to use eye drops?” Subjects who, in addition to complaining of ocular dryness sensation, exhibit at least one of the following symptoms of ocular discomfort: burning, stinging, grittiness, foreign body sensation, or ocular irritation Subjects with a tear film break-up time (TFBUT) <10 seconds Subjects who will possibly comply with the study procedures
Exclusion criteria	Subjects who answer “none of the time” to the question “how often have your eyes felt dry enough to want to use eye drops?” Subjects with a tear film break-up time (TFBUT) ≥10 seconds Subjects who have had refractive eye surgery in the last 6 months Subjects that use concurrent ocular treatment, not including lubricant eye drops or lubricants Subjects known to be allergic to any of the components of Systane Simultaneous participation in other medical studies

Table 2 Percentage of subjects’ current/prior medications, lubricating eye drops, and ocular pathologies at screening visit

	Medication or ocular pathology	Number of subjects (%)
Ocular treatments	Hyaluronic acid	16 (32)
	Eye drops/Hyalistil	7 (14)
	Gental	4 (8)
	Benzalkonium chloride/Celluvisc	3 (6)
	Carbomer/Cellufresh/Hyaluronate/Siccafluid/sodium chloride	2 (4)
	Hylocomod/Lacrinorm/Retinol/Systane/Tetramil	1 (2)
Ongoing ocular pathology	Cataract	2 (4)
	Pinguecola	1 (2)
	Pseudophakia	1 (2)
	Strabismus	1 (2)
Prior ocular pathology	Cataract surgery	1 (2)
	Pseudophakia	1 (2)
	Retinal detachment	1 (2)

Figure 2 Average increase in tear film break-up time (TFBUT) from baseline (Day 0) to endpoint visit (Day 28). ^*p = 0.0001.

Figure 3 Percent improvement of patients with ocular discomfort symptoms.

Figure 4 Subjects’ satisfaction with the improvement of their subjective symptoms at endpoint visit (Day 28) compared with baseline visit (Day 0).